Tag Archives: PDT

PRNews

Tetracore® Inc. Announces European Approval of the T-COR 8™ Portable Real-time PCR Thermocycler

The next generation molecular diagnostics platform introduces novel connectivity solution designed to bring testing closer to the patient

ROCKVILLE, Maryland, Sept. 18, 2017 /PRNewswire/ — Tetracore today announced that the T-COR 8 portable real-time PCR thermocycler has achieved CE-IVD status under the European Directive on In Vitro Diagnostic Medical Devices.

The T-COR 8, and proprietary software delivers healthcare providers with a simple, flexible, and accessible molecular diagnostics platform. This unique, and easy to use point-of-care (POC) diagnostic system enables real-time molecular testing in hospitals, clinics, physician offices, and field applications. 

Healthcare providers rely on molecular testing to produce accurate identification of infectious agents to aid in selecting targeted therapies quickly. Advances in access to molecular testing support global clinical efforts to improve antibiotic stewardship. Most importantly, near patient diagnostics permits appropriate treatment to begin immediately. Designed for the point of care, the T-COR 8 brings molecular infectious disease testing closer to the patient.

“We are focused on delivering testing to where it is most needed, regardless of the setting,” explains Dr. Bill Nelson MD, CEO of Tetracore. “The T-COR 8 empowers more healthcare providers to perform critical tests where it is needed most.” Tetracore is developing several diagnostic tests for the system targeting respiratory viruses, hospital acquired infections, and gastrointestinal infectious disease panels. Along with the proprietary content under development, the T-COR 8 is capable of performing molecular tests in an “open” mode, allowing researchers and developers to create new tests on the next generation instrument using the built-in custom protocol creator.

The T-COR 8 Features Include:

  • “Cloud” ready and networkable (WiFi/ethernet) for remote access and data download
  • 8 independently programmable wells
  • Random access instrument, allowing multiple protocols simultaneously
  • 10.4″ (26.4cm) touch screen w/virtual keyboard
  • Can be plugged in or run on the built-in battery (up to 4 hours of continuous testing)
  • Integrated barcode scanner
  • Download report via network or USB thumb drive

About Tetracore, Inc.
Tetracore is a biotechnology company specializing in the development and manufacture of diagnostic devices and assays for the detection of infectious diseases. Located in the Biotechnology Corridor in Rockville, Maryland. Tetracore was founded in 1998 by former United Nations Special Commission biological weapons inspectors and scientists of the Naval Medical Research Institute in Bethesda, Maryland.  For more information visit www.tetracore.com or contact us at jkelly@tetracore.com.

Source: Tetracore, Inc.

PRNews

Vatech Introduces the PaX-i Insight – the Latest Evolution in 2D Imaging

FORT LEE, N.J., Sept. 1, 2017 /PRNewswire/ —  Vatech officially launches the PaX-i Insight, the next generation of panoramic technology. PaX-i Insight aims to deliver an astonishing feature of adding depths to a panoramic image.


Depth added panoramic image

The all new PaX-i Insight features the ‘Insight Pan’, which is the 4th generation of panoramic radiography presented by Vatech for the first time in the market. While the conventional panoramic systems may miss important details which land outside of a single focal trough, the PaX-i Insight is capable of taking multi-layered images and providing in-depth look across a single focal trough.

Having the option to choose from a variety of images, the Insight Pan offers clinicians to explore 41 images (each sliced in 1 mm) when exploring their region of interest. This feature not only provides an accurate diagnosis for periapical diseases, periodontitis and pericoronitis but also allows clinicians to find hidden roots and canals.

In the case studies released by Vatech, visible fractured roots are often ‘missed out’ in conventional panoramic images with a single layer. Utilizing the PaX-i Insight’s ‘multi-slice’ mode, clinicians can discover buccal roots by examining each root and its periodontal ligament separately.

One notable feature of the PaX-i Insight is the 1.9 second acquisition time. Cephalometry radiography is an essential part of an orthodontic treatment and yet, it was not always easy to acquire a superb image quality that clinicians desire due to the motion artifact. Standing still for 12 seconds is difficult especially for children and teenagers. Furthermore, any movement during the image acquisition would leave clinicians with blurred images. Now with PaX-i Insight’s rapid ceph technology, clinicians can obtain accurate images in the shortest time span by minimizing motion artifacts.

Besides the functionality of the PaX-i Insight, the user-friendly EzDent-i software serves as a powerful solution to maximize the capability of the PaX-i Insight. The Easy-to-use interface allows clinicians to be more efficient with treatment planning and patient consultation. An efficient practice leads to a much better standard of care delivered to the patients.

“We are glad to present Vatech’s latest innovation which fascinated many clinicians at the IDS 2017. The new product will not only reduce the number of retakes by accurately exploring anatomical structures of the teeth but also enable faster diagnostic workflow. Since PaX-i Insight offers a unique feature which other products could not produce, we are all eager to see how this new product will transform the way clinicians work on their cases and communicate with their patients,” said Brian Hwang, CEO of Vatech America.

PaX-i Insight will make its first release in the United States. Shortly, the new product will be introduced to other global markets throughout the year; including Germany, Italy and France. For more information, please visit www.vatechamerica.com.

About Vatech America Inc.

Vatech is a leading provider of digital dental radiography products. As the US subsidiary of Vatech Co., Ltd., Vatech America is dedicated solely to innovative digital dental X-ray imaging technologies that aid dentists and ultimately help to improve the health of dental patients. The company is responsible for technological advances in recent years that offer every American dental practice, from small to large, endless possibilities to achieve higher standards.

PR Contact
June Chang
+1-201-210-5028
jchang@vatechamerica.com 
Vatech America


PaX-i Insight

View original content with multimedia:http://www.prnewswire.com/news-releases/vatech-introduces-the-pax-i-insight—the-latest-evolution-in-2d-imaging-300512079.html

Source: Vatech Co., Ltd.

PRNews

European XFEL: World’s Largest X-ray Laser to Launch in Hamburg

HAMBURG, Germany, Sept. 1, 2017 /PRNewswire/ —

From 1 September 2017, the European XFEL – the world‘s biggest X-ray laser – will be in regular operation. The €1.22 billion research facility in the Hamburg Metropolitan Region involves eleven European countries. 

The facility is a project of superlatives: with 27,000 X-ray laser flashes per second and a luminance a billion times higher than that of the best conventional X-ray sources, XFEL will open up entirely new research opportunities and help transcend the current boundaries of scientific research. It will enable international scientists to decipher the molecular composition of viruses and cells, take three-dimensional images of the nanoworld, film chemical reactions and study processes occurring deep inside planets. XFEL will help develop e.g. new medication and new materials.

This Friday, the facility will be launched by Germany’s Research Minister Johanna Wanka, Hamburg’s First Mayor Olaf Scholz, Schleswig-Holstein’s Science Minister Karin Prien, Russia’s Presidential Advisor Andrei Fursenko, French Research Minister Frédérique Vidal and other high-ranking representatives. They will be joined by several external researchers, who are currently preparing for their first experiments in mid-September.

XFEL is a non-profit organisation that closely collaborates with DESY Hamburg and other international institutions. It employs about 300 people. With a cost of €1.22 billion for construction and launch and a 3.4-kilometre tunnel system that extends to the state of Schleswig-Holstein, it is among Europe’s biggest and most ambitious research projects. Eleven countries are involved: Denmark, France, Germany, Hungary, Italy, Poland, Russia, Slovakia, Spain, Sweden, Switzerland; the UK is in the process of joining. For Hamburg as a science and business location, XFEL marks a further step in establishing itself as an international innovation hub.

More about XFEL: http://www.xfel.eu
More on Hamburg: http://www.hamburg.com

Hamburg Marketing
Guido Neumann
+49-40-300-583    
guido.neumann@marketing.hamburg.de

European XFEL GmbH
Dr Bernd Ebeling
+49-40-8998-6921
press@xfel.eu

PRNews

Merck Opens its First Customer Food Safety Studio

– New Food Safety Studio in Bellevue, Washington, serves as global center for innovation and collaboration

– Demonstration and training lab space extends product and process development to customers

DARMSTADT, Germany, Aug. 30, 2017 /PRNewswire/ — Merck, a leading science and technology company, has opened its first global Food Safety Studio in Bellevue, Washington for manufacturers of all types of food (beef, poultry, produce, etc.) to collaborate with Merck scientists on developing safety products for rapid detection of foodborne pathogens.

The new 5,300-square foot center gives customers access to a complete food safety workflow, from raw materials testing to finished-product safety testing, to help find, correct and prevent hazards within the food supply chain. The center allows customers to work with many manual or automated food safety products such as testing kits and hygiene swabs that are critical to maintaining safety throughout the manufacturing process.

“The opening of Merck’s Food Safety Studio demonstrates our commitment to ensuring the safety of the global food supply,” said Jean-Charles Wirth, Head of the Applied Solutions business unit, Life Science at Merck. “We are bringing teams together in a workspace designed to foster open innovation and collaboration with the goal of becoming the leader in food safety testing.”

According to the World Health Organization, an estimated 600 million people in the world — almost one-in-10 — fall ill after eating contaminated food, and 420,000 die every year.

Merck, which earlier this year acquired BioControl Systems, a global leader in food safety testing, helps customers protect the global food supply by providing a comprehensive portfolio of state-of-the-art testing technologies.

Customer visits are being scheduled for the new Food Safety Studio, which features a Food Safety Demonstration Center designed with a classroom setting and demonstration lab.

All Merck news releases are distributed by email at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

About Merck
Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of €15 billion in 66 countries.

Founded in 1668, Merck is the world’s oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck holds the global rights to the “Merck” name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

PRNews

Why do hair loss prevention and treatment industries pay attention to P1P, a cell-regenerating substance developed in Korea?

-Its effectiveness in overcoming and preventing stress hair loss comes into light

ANYANG, South Korea, Aug. 24, 2017 /PRNewswire/ — P1P (Phytosphingosine 1 Phosphate), a cell-regenerating substance developed in Korea, which is thought to be effective in overcoming hair loss caused by stress, is now drawing attention from the domestic hair loss prevention and treatment industry.


Dr. Myung-Joon Choi of KAIST who released P1P

It was learned that ‘S1P(Sphingosine 1 Phosphate),’ a substance found minimally in the blood, helps to regenerate cells in the body and prevent aging, is effective in preventing necrocytosis due to stress. However, the idea did not lead to the development of products owing to expensive prices.

Under such circumstances, a team of doctors at KAIST continued to delve into the matter in search of its analogs, and succeeded in identifying P1P. By applying P1P to cosmetic and hair loss prevention products, ‘P1P’, a ‘phytosia’ and aesthetic skin care brand, was launched into the market, earning a patent associated with prevention and treatment of hair loss, and a composition for hair growth. From this connection, a skin and hair society in Europe announced the effect of P1P on the mechanism of hair growth.

Dr. Myung-Joon Choi of KAIST who released P1P said, “While studies are actively under way on the application of P1P worldwide, the projects have met a limitation, that is, it is prohibitively expensive, making it a project of low marketability. Under such circumstances, I am so glad that we managed to open the possibility of commercializing the substance since we have secured a technology of synthesizing the substance for mass production. We will continue to work steadily on the project to introduce better products.” 

The P1P substance developed by Korea’s phyto-associated industries are expected to find extensive applications in the domestic medical and bio-industry for stem cell culture technology and the treatment of degenerative neurological diseases.

Contacts:

PHYTOS Co., Ltd.
Myeongjun Choi
Mobile: +82)10-9369-5339
Office: +82)70-7404-6642
Email: myeongjun@p1p.kr

View original content with multimedia:http://www.prnewswire.com/news-releases/why-do-hair-loss-prevention-and-treatment-industries-pay-attention-to-p1p-a-cell-regenerating-substance-developed-in-korea-300509167.html

PRNews

Crowdfunding Success of OYO Fitness’s DoubleFlex Gym Spreads Globally

KANSAS CITY, Miss., Aug. 16, 2017 /PRNewswire/ — After becoming the second highest funded Kickstarter fitness product in history, Kansas City-based OYO Fitness has now launched their DoubleFlex Black Portable Gym on the Backer Founder crowdfunding site in Taiwan. The company’s foray into overseas markets will be followed by additional crowd funding launches on other global sites next month. This personal gym features patented SpiraFlex technology which provides the same benefits as weight training. SpiraFlex has been used by NASA astronauts on the International Space Station and in the Bowflex Revolution home gym.


A crowdfunding effort for the DoubleFlex Black Portable Gym is now underway in Taiwan.

OYO Fitness has received over $700,000 in orders from backers on Kickstarter, placing it in the top 99.9 percent of all products ever offered on this leading crowdfunding site. Since then, OYO has gone on to raise an additional $226,000 through crowdfunding site Indiegogo, bringing total crowdfunding orders to over $930,000 so far.

On the Taiwanese Backer Founder site, the DoubleFlex Black is available at a pre-order price in two configurations that provide 15 or 25 pounds of resistance and include leg and door attachments for a total body workout. Over 75 exercises can be performed in the comfort of the home, office or on the go.  

“Following our success on Kickstarter and Indiegogo, we are thrilled to bring the DoubleFlex Black to other global crowdfunding sites at a discounted price before general distribution to consumers and health clubs in December,” said OYO Fitness founder and CEO Paul Francis. “The overwhelming response speaks directly to consumers’ desire for a fitness product that is both efficient and portable, and that can be used anywhere amid today’s busy lives.” The DoubleFlex Black is available for pre-order in Taiwan at: https://www.oyofitness.com.tw

For US and other countries, the DoubleFlex Black is available for pre-order at:
https://igg.me/at/oyo/x/16092817

The closed Kickstarter campaign can be seen at:
http://kck.st/2lmsXZN

Please visit our website at oyofitness.com and Facebook.com/oyofitness to learn more about OYO Fitness and their products that fits fitness into busy lifestyles.

Photo – http://mma.prnewswire.com/media/544925/OYO_Fitness_DoubleFlex_Black.jpg

PRNews

Vista Launches VTO, Providing High-end Health Care Services To High Net-worth Individuals In China

SHENZHEN, China, Aug. 11, 2017 /PRNewswire/ –To cater to the increasing demand for exclusive health care services among the Chinese high net-worth, Vista, a veteran with two decades of high-end medical service experience in China integrated its best medical resources and launched VISTA THE ONE (VTO), a private health care institution targeting high net-worth individuals and families.


VTO

China’s rapid economic development has created exponentially growing numbers of high net-worth individuals. The gradual aging of this group of people has opened the “private doctors” market in China. The targeted demographic of people is more willing to spend on decreasing their health risks in the future. Specifically, to reduce the uncertain threats on their accumulated wealth – the inheritance issues caused by sudden diseases has become one of their most pressing needs.

Yang Kaixiang, Chief Operating Officer of VTO said: “The significant advantages of VTO’s core services compared to the competitive market of “private doctors” lie in Vista’s unique position and experience. Having served China’s high-end community for over 20 years, Vista has absorbed the essence of high-end private doctor services from other countries. Vista has also accumulated affluent professional experience as well as gaining a profound understanding about the customers’ personalized needs. The highly customized service and products have been widely recognized by Vista customers.”

 “VTO provides its members exclusive healthcare services, for example, exclusive medical group, exclusive family follow up, 24/7 VIP hotlines”, added Yang. “In addition, standard VTO membership equips its owner global medical butler services, including top-tier doctors’ appointments around the world, VVIP services through the whole process and VIP priority access to any medical channels. VTO members are also entitled to Vista’s established world-wide emergency medical rescue service, namely the exclusive usage of Vista’s aviation medical plane.”

Besides the individual and family healthcare services for high-end VVIP customers, Vista operates the VTO member community collectively to build an ecosystem surrounding the idea of the “pan-health industry”, providing a communication platform for resource exchange, such as capital investment and business cooperation for elites.

In order to ensure that VTO members enjoy the high-end health services that matches their status, the conditions for joining are comparatively stricter, including no less than RMB 50 million net assets for an individual and no less than RMB 100 million net assets for families. VTO adopts an invitation only membership management model and applications are not accepted.

About Vista

Vista is the first medical institution to enter the “high-end medical” market in China. All its general doctors have more than 10 years of general practice training, with more than 20 years of practice experience. In 2016, Vista was named “The Most Popular Medical Institution” in China for embassies. Vista has signed up with more than 70 high-end commercial health insurance companies around the world, and has mature medical reception capabilities in 139 mainstream hospitals around the world. The Vista Air Rescue Team has accumulated more than 200 hours on its service record and is currently working as a sole medical partner in cooperation with the Chinese National Health Service Commission on the “One-Belt-One-Road” emergency rescue project, which provides Vista customers more effective medical protection in the countries along the belt and road.

View original content with multimedia:http://www.prnewswire.com/news-releases/vista-launches-vto-providing-high-end-health-care-services-to-high-net-worth-individuals-in-china-300503182.html

PRNews

Korea Institute of Science and Technology (KIST) Develops a New Drug for Alzheimer’s Disease

— Development of a new, innovative drug for Alzheimer’s disease overcoming the limits of existing medicines.

— Offering a new hope of developing a global cure for Alzheimer’s disease through technology transfer and clinical trial

SEOUL, South Korea, Aug. 9, 2017 /PRNewswire/ — As the world population is aging, the top priority of leading countries is to come up with solutions that can overcome dementia. Currently, a handful of anti-dementia drugs are used. But most of them just temporarily alleviate symptoms. Recently, there has been a series of failures of global candidate drugs that have been developed based on the conventional treatment mechanism. Due to the failures, now is a good time to develop a drug based on the root cause of dementia.

Through a fruitful collaboration, scientists at KIST, Ki-Duk Park, C. Justin Lee, and Ae-Nim Pae, developed a drug candidate for dementia with excellent drug-like properties and efficacy. The drug candidate (KDS2010) was based on the previous findings that reactive astrocytes, commonly found in the brain of Alzheimer’s patients, generate and secrete GABA, an inhibitory neurotransmitter, causing memory impairment and cognitive impairment (Nature Medicine, 2014).

This synthetic drug developed by the researchers is a substance that can reduce the amount of abnormally produced GABA. It is a drug candidate that can dramatically improve memory and cognitive impairment of Alzheimer’s disease patients.

* GABA: One of the transmitters of the central nervous system of mammals with strong inhibitory effect on neuronal excitability.

Researchers dissolved the drug in water and fed the mice that are genetically modified to mimic Alzheimer’s disease. They conducted Morris water maze and passive avoidance experiments to check the mice’s memory. They found that cognitive functions of the Alzheimer’s mice returned to the normal state. Furthermore, long-term administration of a low dose (1mg/kg) of the drug led to a long-lasting improvement in cognitive functions, even up to 4 weeks of treatment. This is in great contrast to the existing drugs, whose early efficacy is excellent but long-term administration has low efficacy. Furthermore, according to the results of verifying ADME/Tox, the drug candidate effectively transferred to the brain through oral intake and had drug-like properties without biotoxicity and any side effects on other nervous system.


The ability of candidate drug(KDS2010) to restore neuronal spike probabilities compared to pre-existing drug

This drug candidate provides a fundamental treatment option for cognitive function disorders through an entirely new treatment regime. So far it has been tested for long-term efficacy and toxicity. Currently, non-clinical trials are conducted at the GLP level. This could turn out to be a next-generation global drug for Alzheimer’s disease through immediate clinical trials.

On the 31st of May, Byeonggwon Lee, the president of KIST and Sangmin Park, CEO of MegaBioWood, an affiliate of KEMIMEDI(CEO, Geonseop Choi) had a signing ceremony for the technology transfer on “Drug Candidate for Alzheimer’s disease” at the KIST Seoul Campus. The total amount of the technology transfer contract was for 6 million US dollars, including $500,000 upfront payment and 5.5 million US dollars as a milestone technology payment. The running royalty was signed for 3% of net sales.

KIST (Korea Institute of Science and Technology)

Dr. C Justin Lee
Tel. +82-2-958-6940
e-mail. cjl@kist.re.kr

Dr. Ki-Duk Park
Tel. +82-2-958-5132
e-mail. kdpark@kist.re.kr

View original content with multimedia:http://www.prnewswire.com/news-releases/korea-institute-of-science-and-technology-kist-develops-a-new-drug-for-alzheimers-disease-300501300.html

PRNews

INSTI HIV Self Test Receives Global Fund Classification for Procurement

bioLytical’s INSTI approved by UNITAID and Global Fund expert panel

RICHMOND, British Columbia, July 6, 2017 /PRNewswire/ — bioLytical Laboratories, a world leader in rapid infectious disease tests, is pleased to announce that its INSTI HIV Self Test has been designated by the Global Fund as eligible for procurement by purchasing entities entitled to access Global Fund and UNITAID resources.


INSTI HIV Self Test Receives Global Fund Classification for Procurement

The INSTI HIV Self Test is now eligible for procurement by organizations accessing Global Fund and/or UNITAID funding for their HIV self-test pilot programs that empower individuals to take control of their own health.

“We are very pleased to be awarded this designation by the Global Fund’s Expert Review Panel” said Livleen Veslemes, Chief Operating Officer of bioLytical Laboratories. “In anticipation of significant global demand for a blood-based self-test, we placed a second automated bottling line into service earlier this year to augment the test device production equipment which is designed to produce 1 test per second. We are also investing further into process scale-up, facility optimization, warehouse expansion and evaluating automation of packaging to meet projections from international markets while maintaining the highest product quality standards.”

The Global Fund’s Expert Review Panel for Diagnostics is a mechanism to expedite access to innovative diagnostic products for one year. During this period, bioLytical will pursue World Health Organization prequalification along with approval from another stringent regulatory agency, such as CE marking, of its self-test version for low and middle income countries (LMICs).

Being a market leader in point-of-care HIV tests in major markets across Europe and North America, healthcare providers trust the INSTI brand because it delivers the accurate information and provides instant results for their patients. The INSTI product range is built on a strong foundation of peer-reviewed science and regulatory approvals and supported by over 14 years of expertise, quality, and innovation in medical diagnostics.

About bioLytical Laboratories Inc.

bioLytical Laboratories Inc. is a privately owned Canadian company engaged in the research, development and commercialization of rapid, point of care in vitro medical diagnostics using its proprietary INSTI technology platform.  With a world-wide footprint of regulatory approvals including US FDA approval, Health Canada approval and CE mark, bioLytical markets and sells its INSTI HIV test globally and INSTI HIV/Syphilis Multiplex test in Europe.  The INSTI product line provides highly accurate test results in 60 seconds or less, far faster than the 15-20 minutes required for competitors’ tests based on lateral flow technology.  bioLytical has an active R&D program with a pipeline that includes tests for diseases such as Zika, Hepatitis C and Ebola, among others.  The company also provides contract services to adapt the INSTI platform to meet custom functional and technical diagnostic testing requirements.  For more information, please visit www.biolytical.com.

Contact: Robert Mackie, info@biolytical.com, +1-604-204-6784

Photo – http://mma.prnewswire.com/media/530919/bioLytical_INSTI_HIV_Self_Test.jpg

PRNews

PAVIGYM: New Fitness Model Unveiled in the UK – PRAMA to be Introduced at Harbour Club Kensington

LONDON, July 4, 2017 /PRNewswire/ — The international fitness training concept PRAMA has announced its arrival in London this month, with its debut studio at the Harbour Club Kensington.

PAVIGYM is the company behind the new concept. CEO of PAVIGYM and creator of PRAMA, Marcos Requena describes the concept:

“No treadmills. No rower. No exercise bike. PRAMA combines great instructors, light and music with workouts designed for training strength, speed, agility and more,” he said. “Interactive screens, pressure sensitive floors and walls and lighting combinations, it tracks heart rate, times your sprints and interacts with you.”

But Mr Requena affirms that it is not all fun and games. For Harbour Club Kensington, Sinead Johnson says: “Harbour Club Kensington is the first club in London to offer a new concept in fitness: PRAMA. PRAMA allows us to recreate different experiences and signature programmes for everyone to enjoy in a single space.”

Jennifer Coccia is Fitness Director at Asphalt Green in New York City and their PRAMA studio, branded AG6. Jennifer describes the merit of the PRAMA method: “We chose PRAMA because depending on how you program the system, it can be for beginners to fitness or our elite athletes. For the athlete side, the reaction-time training is hugely valuable to us, because that is a very difficult component to train outside of a competition. It was important for us to be all-inclusive in this space right through to kids too and we use this concept when training our competitive youth teams; we have seen great results in their performance both on and off the field.”

ABOUT PAVIGYM

PAVIGYM is dedicated to the innovative design of flooring and interactive solutions for the global fitness industry.

Established in the 1960s producing high performance athletic soling, by 1996, PAVIGYM was the world’s first premium flooring company, combining traditional manufacturing with cutting-edge technology.

The evolution of PAVIGYM’s flooring technology continued and in 2008, PAVIGYM was the first company to introduce floor markings into the fitness arena. In-house advances in software capabilities led to the creation of a second industry-first in 2012: PAVIGYM interactive flooring solutions. With applications beyond the floor, PAVIGYM went 360 with this know-how in 2014 introducing PRAMA: a combination of LED enriched stations, pressure sensitive floors and walls, different lighting options controlled at the touch of a button, custom-built to any space.

With a 90-strong team based out of PAVIGYM’s headquarters in Alicante, Spain, six running satellite offices across the globe and 65 distributors representing 93 countries, more than 100 members of the team join in pursuit of a common mission: To provide the best combination of performance flooring, interactive technology, inspiring designs, and ready-to-use programming, so that whomever the end user may be [body-type, age and level], the experience is wholly engaging and feels as intuitive as child’s play.

Contact: Emma Thornton, TPN, emma@theprojectnetworkand.co +447585415754

Video: https://www.youtube.com/watch?v=XZEQlEK2wsQ

Video: https://www.youtube.com/watch?v=AvUTnhMH9Fo